(Q33569049)

28 July 2017

title

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. (English)

1 reference

multicenter clinical trial

28 July 2017

main subject

phase II clinical trial

0 references

0 references

1 reference

Kostandinos Sideras

9

0 references

Charles Erlichman

22

object named as

Charles Erlichman

1 reference

28 July 2017

1

Keith C Bible

1 reference

28 July 2017

3

Julian R Molina

1 reference

28 July 2017

2

Vera J Suman

1 reference

28 July 2017

Robert C Smallridge

4

1 reference

28 July 2017

William J Maples

5

1 reference

28 July 2017

Michael E Menefee

6

1 reference

28 July 2017

Joseph Rubin

7

1 reference

28 July 2017

Nina Karlin

8

1 reference

28 July 2017

John C Morris

10

1 reference

28 July 2017

Bryan McIver

11

1 reference

28 July 2017

Ian Hay

12

1 reference

28 July 2017

Vahab Fatourechi

13

1 reference

28 July 2017

Jill K Burton

14

1 reference

28 July 2017

Kevin P Webster

15

1 reference

28 July 2017

Carolyn Bieber

16

1 reference

28 July 2017

Anne M Traynor

17

1 reference

28 July 2017

Patrick J Flynn

18

1 reference

28 July 2017

Boon Cher Goh

19

1 reference

28 July 2017

Crescent R Isham

20

1 reference

28 July 2017

Pamela Harris

21

1 reference

28 July 2017

Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium

23

1 reference

28 July 2017

language of work or name

English

0 references

publication date

25 February 2014

1 reference

The Journal of Clinical Endocrinology and Metabolism

28 July 2017

published in

1 reference

28 July 2017

volume

99

1 reference

28 July 2017

issue

5

1 reference

28 July 2017

page(s)

1687-1693

1 reference

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010705

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010705

Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010705

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010705

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010705

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010705

Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010705

Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010705

Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010705

Sorafenib in metastatic thyroid cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010705

Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010705

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4010705

A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24606083

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Medullary thyroid carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24606083

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1210/JC.2013-3713

1 reference

28 July 2017

1 reference

28 July 2017

1 reference